Learn about our commitment to FGFR-driven diseases
Discover the role of FGFR inhibition
Learn about PROPEL and PROPEL 2
Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration To Co-Develop and Commercialize Infigratinib in Oncology
I am an HCP and would like to someone from QED to contact me.
1800 Owens St, 12th Floor, San Francisco, CA 94158
For additional information, reach out to [email protected]
By selecting “Proceed” you will leave QEDTx.com and be directed to an external website.